drugset / Trial / NCT02697045

Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch

NCT02697045

Phase 4 Completed 23 enrolled Abdi İbrahim Otsuka
NaSingle-groupOpen-labelTreatment

Summary

Nautralsitic, Open-label, Single Arm, Uncontrolled Study Evaluating the Effects of Long Acting Injectable (LAI) on Phychosocial Functioning Congitive Functioning and Patient Reported Acceptability of Treatment 'Reported Acceptability of Treatment' Regarding Quality of Life Subjective Well-being Under Neuroleptic Medication in Schizophrenia Patients

Timeline

Start
2017-01-04
Primary completion
2018-03-31
Completion
2018-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 400 mg Intramuscular

Indications